World Stroke Congress 2024 – oral presentation

We are pleased to announce that our founder & CEO, Dr. Manuel BLANC, will be representing Lys Therapeutics at the World Stroke Congress 2024 in #AbuDhabi this October 23-26. 🧠✨

During the congress, we will also be presenting new data on our first-in-class lead antibody, #LYS241, which protects the brain from neuro-inflammatory and neurodegenerative cascades. LYS241 has a perfect fit with the current standard of care, including thrombolysis with rtPA and TNK, as well as mechanical thrombectomy, while also offering the potential to function as a standalone treatment.

Join us as we explore the latest advancements in #Stroke research and #neurology, connecting with global experts to drive innovation and improve patient outcomes.

At Lys Therapeutics, we are committed to pushing the boundaries in treating neurovascular diseases such as stroke, as well as neurodegenerative disorders like Parkinson’s Disease, Progressive MS, and other rare conditions.

We look forward to insightful discussions and collaborations at #WSC2024!